Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
2015
Kannel, 1985, Lipids, diabetes, and coronary heart disease: insights from the Framingham Study, Am Heart J, 110, 1100, 10.1016/0002-8703(85)90224-8
Donahoe, 2007, Diabetes and mortality following acute coronary syndromes, JAMA, 298, 765, 10.1001/jama.298.7.765
Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1
2017, 9. Cardiovascular disease and risk management, Diabetes Care, 40, S75
Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6
Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860
Besseling, 2015, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus, JAMA, 313, 1029, 10.1001/jama.2015.1206
Swerdlow, 2015, HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, Lancet, 385, 351, 10.1016/S0140-6736(14)61183-1
Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664
Sabatine, 2016, Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, Am Heart J, 173, 94, 10.1016/j.ahj.2015.11.015
2013, Standards of medical care in diabetes—2013, Diabetes Care, 36, S11
2008, Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X
Landmesser, 2017, European Society of Cardiology/European Atherosclerosis Society task force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk, Eur Heart J, 38, 2245
Jellinger, 2017, American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease—executive summary, Endocr Pract, 23, 479, 10.4158/EP171764.GL
Colhoun, 2016, No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies, Eur Heart J, 37, 2981, 10.1093/eurheartj/ehw292
Ridker, 2017, Cardiovascular efficacy and safety of bococizumab in high-risk patients, N Engl J Med, 376, 1527, 10.1056/NEJMoa1701488
Giugliano, 2017, Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, Lancet, 10.1016/S0140-6736(17)32290-0
Erqou, 2014, Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis, Diabetologia, 57, 2444, 10.1007/s00125-014-3374-x
Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet, 380, 565, 10.1016/S0140-6736(12)61190-8
Ference, 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, N Engl J Med, 375, 2144, 10.1056/NEJMoa1604304
Schmidt, 2017, PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study, Lancet Diabetes Endocrinol, 5, 97, 10.1016/S2213-8587(16)30396-5
Lotta, 2016, Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis, JAMA, 316, 1383, 10.1001/jama.2016.14568
White, 2016, Association of lipid fractions with risks for coronary artery disease and diabetes, JAMA Cardiol, 1, 692, 10.1001/jamacardio.2016.1884
Waters, 2011, Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials, J Am Coll Cardiol, 57, 1535, 10.1016/j.jacc.2010.10.047
Koren, 2017, Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study, JAMA Cardiol, 2, 598, 10.1001/jamacardio.2017.0747